News
Edwards' Aortic Valve With Resilia Tissue Shows Favorable Durability, Safety and Efficacy Outcomes in Seven Year Data. May 17, 2023 04:25 AM Eastern Daylight Time. NEWBURY, ...
Calcium with control valve (left) and Resilia-tissue valve (right). Photo Credit: Edwards Lifesciences Surgical bioprosthetic aortic valves made with bioengineered Resilia tissue (Edwards Lifesciences ...
EDWARDS' AORTIC VALVE WITH RESILIA TISSUE SHOWS FAVORABLE DURABILITY, SAFETY AND EFFICACY OUTCOMES IN SEVEN YEAR DATA . NEWBURY, May 16 th, 2023 -- Edwards Lifesciences announced new data from the ...
Edwards Lifesciences announced new data from the COMMENCE aortic trial, demonstrating low rates of structural valve deterioration (SVD) in bioprosthetic aortic valves with the company's innovative ...
LOS ANGELES, May 7, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today announced new data from the COMMENCE aortic trial, demonstrating low rates of structural valve deterioration (SVD) in ...
LOS ANGELES, May 7, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today announced new data from the COMMENCE aortic trial, demonstrating low rates of structural valve deterioration (SVD) in ...
LOS ANGELES, May 7, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today announced new data from the COMMENCE aortic trial, demonstrating low rates of structural valve deterioration (SVD) in ...
LOS ANGELES, May 7, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today announced new data from the COMMENCE aortic trial, demonstrating low rates of structural valve deterioration (SVD) in ...
LOS ANGELES, May 7, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today announced new data from the COMMENCE aortic trial, demonstrating low rates of structural valve deterioration (SVD) in ...
LOS ANGELES, May 7, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today announced new data from the COMMENCE aortic trial, demonstrating low rates of structural valve deterioration (SVD) in ...
LOS ANGELES, May 7, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today announced new data from the COMMENCE aortic trial, demonstrating low rates of structural valve deterioration (SVD) in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results